Cargando…

Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer

Numerous clinical studies in an adjuvant setting have been conducted and the combination therapy of 5‐fluorouracil and oxaliplatin has been established as the standard treatment for Stage III and as an option for high‐risk Stage II patients. Biologics such as bevacizumab and antiepidermal growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oki, Eiji, Ando, Koji, Taniguchi, Hiroya, Yoshino, Takayuki, Mori, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786685/ https://www.ncbi.nlm.nih.gov/pubmed/35106413 http://dx.doi.org/10.1002/ags3.12503

Ejemplares similares

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2023)

Recent developments in cancer research: Expectations for a new remedy
por: Ando, Koji, et al.
Publicado: (2021)

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial
por: Yoshino, Takayuki, et al.
Publicado: (2019)

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
por: Yoshino, Takayuki, et al.
Publicado: (2018)

DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy
por: Miyo, Masaaki, et al.
Publicado: (2022)

Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors
por: Akagi, Kiwamu, et al.
Publicado: (2021)

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
por: Collienne, Maike, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients
por: Oki, Eiji, et al.
Publicado: (2021)

Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study
por: Oki, E., et al.
Publicado: (2021)

Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)
por: Miwa, Keisuke, et al.
Publicado: (2021)

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
por: Satake, Hironaga, et al.
Publicado: (2020)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Adjuvant colon cancer chemotherapy: Is there an Indian standard of care?
por: Joshi, Rohit
Publicado: (2013)

CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer
por: Matsuoka, Hiroya, et al.
Publicado: (2020)

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
por: Kotaka, Masahito, et al.
Publicado: (2018)

Laparoscopic Gastrectomy for Gastric Cancer with Peritoneal Dissemination after Induction Chemotherapy
por: Tsutsumi, Satoshi, et al.
Publicado: (2013)

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
por: Iveson, Timothy J., et al.
Publicado: (2021)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
por: Eren, Tulay, et al.
Publicado: (2020)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
por: Miyo, Masaaki, et al.
Publicado: (2020)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

The effects of ARID1A mutations on colorectal cancer and associations with PD‐L1 expression by stromal cells
por: Kamori, Tomohiro, et al.
Publicado: (2021)

Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma
por: Koga, Naomichi, et al.
Publicado: (2021)

Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
por: Teufel, Andreas, et al.
Publicado: (2015)

Adjuvant chemotherapy for stage II colon cancer: who really needs it
por: Yang, Yan, et al.
Publicado: (2018)

Correction: Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
por: Eren, Tulay, et al.
Publicado: (2020)

The Prognostic Value of Adjuvant Chemotherapy in Colon Cancer With Solitary Tumor Deposit
por: Lin, Qiangkang, et al.
Publicado: (2022)

Updated Adjuvant Chemotherapy for Gastric Cancer
por: Takayama, Toshizo, et al.
Publicado: (2023)

The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients
por: Taketani, Kenji, et al.
Publicado: (2013)

Colon cancer with extensive invasion of the abdominal wall treated with neoadjuvant chemotherapy and a free anterolateral thigh flap
por: Aritake, Tsukasa, et al.
Publicado: (2022)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

DNA replication stress and cancer chemotherapy
por: Kitao, Hiroyuki, et al.
Publicado: (2017)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
por: Lee, Mok-Won, et al.
Publicado: (2021)

Extramedullary Hematopoiesis in Mismatch Repair Deficient Colon Cancer Patient on Adjuvant Chemotherapy
por: De Leo, Edward K, et al.
Publicado: (2021)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dcl0otog74uri0s18abjfk6058